Compass Therapeutics 将来の成長

Future 基準チェック /26

Compass Therapeuticsは、52.5%と73.7%でそれぞれ年率52.5%で利益と収益が成長すると予測される一方、EPSはgrowで52.3%年率。

主要情報

52.5%

収益成長率

52.3%

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	73.7%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	20 Nov 2024

今後の成長に関する最新情報

Recent updates

Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Sep 20

Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial

Oct 11

業績と収益の成長予測

NasdaqCM:CMPX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	68	-69	N/A	-37	7
12/31/2025	5	-66	N/A	-46	7
12/31/2024	1	-49	N/A	-46	7
9/30/2024	1	-48	-48	-48	N/A
6/30/2024	1	-47	-43	-43	N/A
3/31/2024	N/A	-45	-42	-42	N/A
12/31/2023	N/A	-42	-41	-41	N/A
9/30/2023	N/A	-41	-39	-39	N/A
6/30/2023	N/A	-43	-44	-44	N/A
3/31/2023	N/A	-40	-38	-38	N/A
12/31/2022	N/A	-39	-34	-34	N/A
9/30/2022	N/A	-41	-29	-28	N/A
6/30/2022	N/A	-35	-22	-21	N/A
3/31/2022	N/A	-82	-24	-22	N/A
12/31/2021	N/A	-82	-22	-20	N/A
9/30/2021	N/A	-78	-23	-22	N/A
6/30/2021	N/A	-81	-26	-25	N/A
3/31/2021	N/A	-31	-25	-25	N/A
12/31/2020	N/A	-29	-27	-27	N/A
9/30/2020	N/A	-28	-26	-26	N/A
6/30/2020	N/A	-27	-26	-25	N/A
3/31/2020	N/A	-30	-29	-29	N/A
12/31/2019	N/A	-35	-32	-32	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CMPX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CMPX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CMPX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CMPXの収益 ( 73.7% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: CMPXの収益 ( 73.7% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CMPXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Compass Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 49%

Consensus revenue estimates increase by 32%

Price target decreased by 13% to US$8.00

Price target increased to US$9.46

Price target increased to US$9.67

Price target decreased to US$8.86

Recent updates

Consensus revenue estimates increase by 49%

New minor risk - Profitability

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Consensus revenue estimates increase by 32%

Price target decreased by 13% to US$8.00

Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 2500 Growth Index

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Compass Therapeutics, Inc. Announces Management Changes

Compass Therapeutics to Present Phase 1 Data for CTX-471, a Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

Compass Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Compass Therapeutics, Inc. Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated

Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

New minor risk - Shareholder dilution

We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Compass Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 9, 2024

Compass Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 9, 2024

Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Ankyra Therapeutics Names Robert V. Tighe as Chief Scientific Officer

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Co-Founder recently bought US$80k worth of stock

Co-Founder recently bought US$77k worth of stock

Compass Therapeutics, Inc. Appoints David Wurzer as Class III Director, Member and Chairman of the Audit Committee

Price target increased to US$9.46

Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer

Compass Therapeutics, Inc. Announces That the First Patient Has Been Dosed in the Phase 1B Study of CTX-471 in Combination with Keytruda®, Merck’S Anti-PD-1 Therapy

President & COO recently sold US$97k worth of stock

Price target increased to US$9.67

High number of new and inexperienced directors

Compass Therapeutics, Inc. announced that it expects to receive $80.25 million in funding from a group of investors

Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial

High number of new and inexperienced directors

Compass Therapeutics, Inc. Announces Resignation of Stephen Squinto as Member of the Board of Directors, Effective August 31, 2022

High number of new and inexperienced directors

Co-Founder recently bought US$61k worth of stock

Co-Founder recently bought US$50k worth of stock

Compass Therapeutics, Inc. Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers

High number of new and inexperienced directors

Price target decreased to US$8.86

Compass Therapeutics Announces Management Appointments

Compass Therapeutics, Inc. Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting

Compass Therapeutics, Inc. Announces Resignation of Brett Kaplan of the Board of Directors

Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)

High number of new and inexperienced directors

Compass Therapeutics, Inc. (OTCPK:CMPX) entered into a definitive merger agreement to acquire TRIGR Therapeutics, Inc. for $45.2 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘